Tango Therapeutics’ treatment of malignant glioma was granted orphan designation by the FDA, according to a post to the agency’s website. Reference Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNGX:
- Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights
- Tango Therapeutics to Participate in Upcoming Investor Conferences
- Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
